Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | XBP1 | P17861 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19410144 | 0.89 | TPSAB1 (0.34) | MAPTXBP1NPSR1TDP1POLB | |
| SCHEMBL31189245 | 0.89 | TPSAB1 (0.34) | MAPTXBP1NPSR1TDP1POLB | |
| SCHEMBL19410228 | 0.79 | MTNR1A (0.33) | — | |
| SCHEMBL19410193 | 0.77 | L3MBTL1 (0.44) | — | |
| SCHEMBL19410146 | 0.69 | SLC7A5 (0.38) | MAPT | |
| SCHEMBL19410199 | 0.67 | PLK1 (0.46) | MAPT | |
| SCHEMBL19410213 | 0.65 | ALDH1A1 (0.43) | NPSR1POLB | |
| SCHEMBL19410194 | 0.63 | PLK1 (0.42) | — | |
| SCHEMBL16284728 | 0.63 | SYK (0.50) | MAPTNPSR1TDP1POLB | |
| SCHEMBL19410169 | 0.62 | SLC16A3 (0.36) | NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10358463-B2 | Immunomodulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-07-23 | — | — | US | disclosed |
| US-20170283463-A1 | IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2017-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170283463-A1 | IMMUNOMODULATORS | CD274, PDCD1, PDCD1LG2 | MAPT 3711/4885XBP1 1222/4885NPSR1 3065/4885 |
| US-10358463-B2 | Immunomodulators | CD274, PDCD1, PDCD1LG2 | MAPT 3711/4885XBP1 1222/4885NPSR1 3065/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.